MOMA Therapeutics, Inc.

Who: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi